B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in...

Area of Science:

• Immunology
• Systems Biology
• Pharmacology

Background:

• Rituximab (RTX), an anti-CD20 monoclonal antibody, is used for autoimmune diseases like rheumatoid arthritis (RA).
• Variability in patient response to RTX treatment presents a clinical challenge.
• Understanding B cell dynamics is crucial for optimizing RTX therapy.

Purpose of the Study:

• To develop a systems model simulating B cell differentiation and RTX interactions.
• To identify key factors driving therapeutic response and variability in RTX treatment for RA.
• To provide a mechanistic framework for CD20-depletion therapy.

Main Methods:

• Developed a systems model of B cell differentiation, including localization and CD20-RTX complex internalization.
• Integrated pharmacokinetic models for RTX and glucocorticoids to simulate clinical data from RA patients.
• Performed global sensitivity analyses to identify critical model parameters and their impact on B cell populations.

Main Results:

• The model accurately captured pharmacodynamic profiles of CD19+, CD20+ cells, and plasmablasts (PBs) in RA patients treated with RTX and glucocorticoids.
• CD20-RTX binding affinity and elimination rate constants were identified as major determinants of CD19+ cell and antibody-secreting cell (ASC) depletion.
• Baseline PB and PC levels were suggested to influence ASCs, potentially explaining treatment response variability.

Conclusions:

• The developed model offers a mechanistic understanding of B cell dynamics in response to CD20-depletion therapy.
• Key drivers of RTX efficacy, including binding affinity and elimination rates, were elucidated.
• B cell dynamics can serve as an indirect biomarker for clinical outcomes, potentially improving RTX therapeutic strategies.